Revolution Medicines, Inc. PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Revolution Medicines, Inc. pe ratio for the quarter ending 2026-06-30 was -22.69, a change of -14.22 year-over-year.
- Revolution Medicines, Inc. pe ratio for the quarter ending 2026-03-31 was -14.18, a change of -4.74 year-over-year.
- Revolution Medicines, Inc. pe ratio for the quarter ending 2025-12-31 was -13.87, a change of -0.32 year-over-year.
- Revolution Medicines, Inc. pe ratio for the quarter ending 2025-09-30 was -9.21, a change of 4.2 year-over-year.
- Revolution Medicines, Inc. pe ratio for fiscal 2026 was -22.69.
- Revolution Medicines, Inc. pe ratio for fiscal 2025 was -13.87, a change of -0.32 from fiscal 2024.
- Revolution Medicines, Inc. pe ratio for fiscal 2024 was -13.55, a change of -2.73 from fiscal 2023.
- Revolution Medicines, Inc. pe ratio for fiscal 2023 was -10.82, a change of -2.16 from fiscal 2022.
- Available history
- 2020-03-31 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |